Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 1/2022

31.01.2022 | Review Article

Hashimoto’s Thyroiditis and Papillary Cancer Thyroid Coexistence Exerts a Protective Effect: a Single Centre Experience

verfasst von: Enrico Battistella, Luca Pomba, Andrea Costantini, Antonio Scapinello, Antonio Toniato

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Papillary thyroid carcinoma (PTC) is the most common malignant tumour of the thyroid and it is often found in association with Hashimoto’s thyroiditis (HT). This concomitance is still under debate. The aim of this study is to investigate the influence of Hashimoto’s thyroiditis in patients with papillary thyroid carcinoma. Two thousand two hundred eighteen patients underwent thyroidectomy in our department between January 2015 and January 2020. Of these, 435 patients had surgery for papillary thyroid carcinoma and form the basis of our studies. The association between PTC and HT was found in 180 patients (41.4%), mostly represented in the female group (78.9%), with a lower median age than patients with PTC without HT. In comparison to patients with PTC alone, the PTC-HT group had less invasive and smaller tumours, as well as less lymph node involvement. Moreover, tumours of patients with PTC-HT were diagnosed earlier. Our data showed that Hashimoto’s thyroiditis may be considered a protective factor when PTC develops. Furthermore, we concluded that patients with PTC and HT had a better prognosis and a lower risk of recurrence than those that did not have HT.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef
2.
Zurück zum Zitat Liu S, Semenciw R, Ugnat AM, Mao Y (2001) Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85(9):1335–1339CrossRef Liu S, Semenciw R, Ugnat AM, Mao Y (2001) Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85(9):1335–1339CrossRef
4.
Zurück zum Zitat Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52CrossRef Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52CrossRef
5.
Zurück zum Zitat Mincer, D. L., & Jialal, I. (2019). Hashimoto thyroiditis. In StatPearls [Internet]. StatPearls Publishing. Mincer, D. L., & Jialal, I. (2019). Hashimoto thyroiditis. In StatPearls [Internet]. StatPearls Publishing.
6.
Zurück zum Zitat Caturegli P, De Remigis A, Rose NR (2014) Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 13(4–5):391–397CrossRef Caturegli P, De Remigis A, Rose NR (2014) Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 13(4–5):391–397CrossRef
7.
Zurück zum Zitat Dailey ME, Lindsay S, Skahen R (1955) Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–297CrossRef Dailey ME, Lindsay S, Skahen R (1955) Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–297CrossRef
8.
Zurück zum Zitat Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, von Buchwald C (2017) Association between Hashimoto’s thyroiditis and thyroid cancer in 64,628 patients. Front Oncol 7:53CrossRef Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, von Buchwald C (2017) Association between Hashimoto’s thyroiditis and thyroid cancer in 64,628 patients. Front Oncol 7:53CrossRef
9.
Zurück zum Zitat Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A (2010) Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 45(3–4):333–337CrossRef Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A (2010) Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 45(3–4):333–337CrossRef
10.
Zurück zum Zitat Fiore E, Latrofa F, Vitti P (2015) Iodine, thyroid autoimmunity and cancer. Eur Thyroid J 4(1):26–35CrossRef Fiore E, Latrofa F, Vitti P (2015) Iodine, thyroid autoimmunity and cancer. Eur Thyroid J 4(1):26–35CrossRef
11.
Zurück zum Zitat Farrell E, Heffron C, Murphy M, O’Leary G, Sheahan P (2017) Impact of lymphocytic thyroiditis on incidence of pathological incidental thyroid carcinoma. Head Neck 39(1):122–127CrossRef Farrell E, Heffron C, Murphy M, O’Leary G, Sheahan P (2017) Impact of lymphocytic thyroiditis on incidence of pathological incidental thyroid carcinoma. Head Neck 39(1):122–127CrossRef
12.
Zurück zum Zitat Jackson D, Handelsman RS, Farrá JC, Lew JI (2020) Increased incidental thyroid cancer in patients with subclinical chronic lymphocytic thyroiditis. J Surg Res 245:115–118CrossRef Jackson D, Handelsman RS, Farrá JC, Lew JI (2020) Increased incidental thyroid cancer in patients with subclinical chronic lymphocytic thyroiditis. J Surg Res 245:115–118CrossRef
13.
Zurück zum Zitat Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, Tsyb AF (2004) Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer 90(11):2219–2224CrossRef Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, Tsyb AF (2004) Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer 90(11):2219–2224CrossRef
14.
Zurück zum Zitat Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, Wingren G (1999) A pooled analysis of case-control studies of thyroid cancer¶ II. Menstrual and reproductive factors. Cancer Causes Control 10(2):143–155CrossRef Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, Wingren G (1999) A pooled analysis of case-control studies of thyroid cancer¶ II. Menstrual and reproductive factors. Cancer Causes Control 10(2):143–155CrossRef
15.
Zurück zum Zitat Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, Jin F (1999) A pooled analysis of case–control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10(6):583–595CrossRef Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, Jin F (1999) A pooled analysis of case–control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10(6):583–595CrossRef
16.
Zurück zum Zitat Musholt TJ, Musholt PB, Petrich T, Oetting G, Knapp WH, Klempnauer J (2000) Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 24(11):1409–1417CrossRef Musholt TJ, Musholt PB, Petrich T, Oetting G, Knapp WH, Klempnauer J (2000) Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 24(11):1409–1417CrossRef
17.
Zurück zum Zitat Soveid M, Monabbati A, Sooratchi L, Dahti S (2007) The effect of iodine prophylaxis on the frequency of thyroiditis and thyroid tumors in Southwest, Iran. Saudi Med J 28(7):1034PubMed Soveid M, Monabbati A, Sooratchi L, Dahti S (2007) The effect of iodine prophylaxis on the frequency of thyroiditis and thyroid tumors in Southwest, Iran. Saudi Med J 28(7):1034PubMed
18.
Zurück zum Zitat Lee JH, Kim Y, Choi JW, Kim YS (2013) The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 168(3):343–349CrossRef Lee JH, Kim Y, Choi JW, Kim YS (2013) The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 168(3):343–349CrossRef
19.
Zurück zum Zitat McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL (2012) Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 97(8):2682–2692CrossRef McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL (2012) Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 97(8):2682–2692CrossRef
20.
Zurück zum Zitat Paparodis RD, Bantouna D, Karvounis E, Imam S, Jaume JC (2020) Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity. J Clin Endocrinol Metab 105(7):dgaa237CrossRef Paparodis RD, Bantouna D, Karvounis E, Imam S, Jaume JC (2020) Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity. J Clin Endocrinol Metab 105(7):dgaa237CrossRef
21.
Zurück zum Zitat Tamimi DM (2002) The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol 10(2):141–146CrossRef Tamimi DM (2002) The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol 10(2):141–146CrossRef
22.
Zurück zum Zitat Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Rothstein JL (1997) Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope 107(1):95–100CrossRef Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Rothstein JL (1997) Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope 107(1):95–100CrossRef
23.
Zurück zum Zitat Unger P, Ewart M, Wang BY, Gan LI, Kohtz DS, Burstein DE (2003) Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Hum Pathol 34(8):764–769CrossRef Unger P, Ewart M, Wang BY, Gan LI, Kohtz DS, Burstein DE (2003) Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Hum Pathol 34(8):764–769CrossRef
24.
Zurück zum Zitat Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, Kim IJ (2011) Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck 33(9):1272–1277CrossRef Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, Kim IJ (2011) Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck 33(9):1272–1277CrossRef
25.
Zurück zum Zitat Zhang Y, Dai J, Wu T, Yang N, Yin Z (2014) The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 140(6):1021–1026CrossRef Zhang Y, Dai J, Wu T, Yang N, Yin Z (2014) The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 140(6):1021–1026CrossRef
26.
Zurück zum Zitat Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, Park J (2011) Clinical relationship between Hashimoto’s thyroiditis and papillary thyroid cancer. Acta Oncol 50(8):1228–1234CrossRef Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, Park J (2011) Clinical relationship between Hashimoto’s thyroiditis and papillary thyroid cancer. Acta Oncol 50(8):1228–1234CrossRef
27.
Zurück zum Zitat Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW, Park CS (2012) Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci 27(8):883–889CrossRef Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW, Park CS (2012) Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci 27(8):883–889CrossRef
28.
Zurück zum Zitat Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA (2013) Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab 98(6):2409–2414CrossRef Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA (2013) Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab 98(6):2409–2414CrossRef
29.
Zurück zum Zitat Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, Troncone G (2017) Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 24(9):485–493CrossRef Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, Troncone G (2017) Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 24(9):485–493CrossRef
Metadaten
Titel
Hashimoto’s Thyroiditis and Papillary Cancer Thyroid Coexistence Exerts a Protective Effect: a Single Centre Experience
verfasst von
Enrico Battistella
Luca Pomba
Andrea Costantini
Antonio Scapinello
Antonio Toniato
Publikationsdatum
31.01.2022
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 1/2022
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-022-01515-9

Weitere Artikel der Ausgabe 1/2022

Indian Journal of Surgical Oncology 1/2022 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.